No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 2 | 2 | 2 | 2 | N/A | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | -1 | -1 | -1 | -1 | -2 | N/A | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
Deltex Medical Group plc, with its global presence encompassing the United Kingdom, the United States, Spain, and Canada, is dedicated to the development, marketing, and distribution of its TrueVue brand of esophageal Doppler hemodynamic monitoring systems. The company's innovative product lineup features: Esophageal Doppler Probes: These probes are engineered to accurately gauge a patient's central vascular blood flow and fluid status by continuously measuring real-time blood velocities within the descending aorta. Loops plots: This technology provides dynamic visualization of aortic blood flow velocity and aortic blood pressure, tracked meticulously with every single heartbeat. High Definition Impedance Cardiography: A non-invasive solution for monitoring cardiac function and fluid balance in conscious patients. PressureWave: An advanced algorithm that performs pulse pressure waveform analysis, particularly valuable during periods of patient instability or when the esophageal Doppler mode (ODM) is not available. Beyond monitoring devices, Deltex Medical also offers the Deltex Medical Esophageal Doppler Simulator. This tool allows clinicians to hone their skills in probe insertion, precise focusing, and waveform interpretation in a controlled, non-patient environment. These systems are critical in a variety of clinical applications, including intensive care for conditions like COVID-19 and sepsis; extensive surgical procedures such as major abdominal, laparoscopic, and spinal operations; cardiac, trauma, and organ transplant interventions; and the crucial post-operative monitoring for acute kidney injury. Founded in 2000, Deltex Medical Group plc is headquartered in Chichester, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Deltex Medical Group plc, with its global presence encompassing the United Kingdom, the United States, Spain, and Canada, is dedicated to the development, marketing, and distribution of its TrueVue brand of esophageal Doppler hemodynamic monitoring systems. The company's innovative product lineup features: Esophageal Doppler Probes: These probes are engineered to accurately gauge a patient's central vascular blood flow and fluid status by continuously measuring real-time blood velocities within the descending aorta. Loops plots: This technology provides dynamic visualization of aortic blood flow velocity and aortic blood pressure, tracked meticulously with every single heartbeat. High Definition Impedance Cardiography: A non-invasive solution for monitoring cardiac function and fluid balance in conscious patients. PressureWave: An advanced algorithm that performs pulse pressure waveform analysis, particularly valuable during periods of patient instability or when the esophageal Doppler mode (ODM) is not available. Beyond monitoring devices, Deltex Medical also offers the Deltex Medical Esophageal Doppler Simulator. This tool allows clinicians to hone their skills in probe insertion, precise focusing, and waveform interpretation in a controlled, non-patient environment. These systems are critical in a variety of clinical applications, including intensive care for conditions like COVID-19 and sepsis; extensive surgical procedures such as major abdominal, laparoscopic, and spinal operations; cardiac, trauma, and organ transplant interventions; and the crucial post-operative monitoring for acute kidney injury. Founded in 2000, Deltex Medical Group plc is headquartered in Chichester, United Kingdom.